摘要
目的:研究PD-1抑制剂对肺癌合并心血管疾病患者的生化指标影响。方法:本研究分析了293例未经过PD-1抑制剂治疗和273例经过PD-1抑制剂治疗的肺癌合并心血管疾病患者的47个生化指标。通过分型方法、热图、ROC曲线和t检验来确定PD-1抑制剂对肺癌合并心血管疾病内在生化物质的影响。结果:通过正交信号校正的偏最小二乘判别分析,实现了高效的两类样本分型,其诊断效率达0.806。通过热图和相关性分析,发现了典型差异生物标志物分子。同时,对典型的岩藻糖甘酶(指标39)、谷草线粒体同工酶(指标41)和中性粒细胞百分比(指标10)进行了诊断效率和显著性分析,这3个指标协同作用可能为后续PD-1抑制剂治疗引发的肺癌合并心血管疾病的监控提供参考意义。结论:多维度生化指标的联合分析有助于更好地理解肺癌合并心血管疾病和PD-1抑制剂治疗的疗效评估,为进一步开展相关研究提供了基础数据和方法学支持。
Objective:This study aims to investigate the impact of PD-1 inhibitors on biochemical parameters in patients with lung cancer and concomitant cardiovascular diseases.Methods:We conducted an analysis involving 293 patients who had not undergone PD-1 inhibitor treatment and 273 patients who had received PD-1 inhibitor therapy.A total of 47 biochemical parameters were assessed.Various strategies,including classification methods,heatmaps,ROC curves,and T-tests,were employed to assess the influence of PD-1 inhibitors on intrinsic biochemical substances in patients with lung cancer and cardiovascular comorbidities.Results:Utilizing orthogonal signal correction and partial least squares discriminant analysis,our study achieved efficient classification of two sample groups,yielding a diagnostic efficiency of 0.806.Heatmaps and correlation analysis identified distinctive differential biomarkers.Furthermore,we conducted diagnostic efficiency and significance analysis for typical markers,namely arabinose(indicator 39),glutamate mitochondrial isoenzyme(indicator 41),and neutrophil percentage(indicator 10).These three markers may synergistically contribute to monitoring lung cancer with concurrent cardiovascular diseases following PD-1 inhibitor therapy.Conclusion:The combined analysis of multidimensional biochemical parameters contributes to a better understanding of the efficacy evaluation of lung cancer with concurrent cardiovascular diseases and PD-1 inhibitor treatment.This study provides essential foundational data and methodological support for further research in this area.
作者
陶金松
李伟章
崔俊友
李健
曹向明
张华
TAO Jinsong;LI Weizhang;CUI Junyou;LI Jian;CAO Xiangming;ZHANG Hua(Department of Cardiology,Jiangyin Hospital Affiliated to Southeast University,Wuxi 214400,China;Department of Oncology,Jiangyin Hospital Affiliated to Southeast University,Wuxi 214400,China)
出处
《黑龙江医药科学》
2024年第2期20-23,共4页
Heilongjiang Medicine and Pharmacy
基金
无锡卫生健康委员会项目,编号:Z202120。
